A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01093157
Recruitment Status : Completed
First Posted : March 25, 2010
Last Update Posted : May 4, 2017
Information provided by (Responsible Party):
University Health Network, Toronto

March 24, 2010
March 25, 2010
May 4, 2017
February 2010
January 2013   (Final data collection date for primary outcome measure)
change in proteinuria from baseline to value at 3 months . [ Time Frame: 3 months ]
Same as current
Complete list of historical versions of study NCT01093157 on Archive Site
  • Complete Remission(CR) or Partial Remission (PR) at 3 months [ Time Frame: 3 months ]
    Definition of proteinuric status. UP = urinary protein (g/24h) Complete remission (CR) UP ≤ 0.3 g Partial remission (PR) Reduction in UP of > 50% plus final UP ≤ 3.5 g but >0.3g Non-response (NR) Reduction in UP of < 50%. (includes increase in UP <50%) Progression Proteinuria increases by > 50%
  • Adverse effects [ Time Frame: Throughout three months of this study and for nine months follow-up ]
    Patients will be directly questioned every two weeks during the drug exposure and then at monthly intervals during follow-up. In addition a contact number will be provided to the subjects to call if they experience any adverse affect or if they suspect adverse effect at any time between specific visits
Same as current
Not Provided
Not Provided
A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
A Dose-finding Pilot Study of ACTH (Adrenocorticotropic Hormone) on the Proteinuria and Serum Lipoprotein Profile in Patients With Idiopathic Membranous Nephropathy (MN)

Membranous Nephropathy (MN) is an immune-mediated kidney disease that affects the glomerulus or the filter that removes toxins from the blood. Damage to the membrane that separates blood from urine results in loss of protein into the urine (proteinuria) and in some cases loss of kidney function.There is no standard specific treatment for MN.

ACTH has a pronounced lipid-lowering effect in healthy individuals, in steroid-treated patients with renal disease and in hemodialysis patients Some studies suggest that prolonged synthetic ACTH therapy may represent an effective therapy in patients with idiopathic MN, more extensive randomized studies with longer follow-up are needed before therapeutic recommendations can be made.

We propose to do a pilot study to test the hypothesis that biologic ACTH, a slow-release formulation of corticotropin extracted from porcine pituitary glands (H.P. Acthar gel) will be effective in reducing proteinuria and improving lipid profile in patients with idiopathic MN.

Not Provided
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Drug: Adrenocorticotrophic hormone ACTH
There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
Other Name: HP Acthar gel
  • Active Comparator: ACTH (HP Acthar gel) 40 units
    Intervention: Drug: Adrenocorticotrophic hormone ACTH
  • Active Comparator: ACTH (HP Acthar gel) 80 units
    Intervention: Drug: Adrenocorticotrophic hormone ACTH
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
February 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:• Idiopathic MN with diagnostic biopsy performed less than 36 months from the time of dose randomization.

  • Patients need to be treated with an ACEI and/or ARB, for at least 3 months prior to ACTH treatment and have adequately controlled blood pressure (BP <130/75 mm Hg in >75% of the readings). Patients with documented evidence of >3 months treatment with maximal Ang II blockade, target BP (BP <130/75 mm Hg in >75% of the readings) and who remain with proteinuria >4.0g/24h may enter the ACTH phase of the study without the need to have the run-in/conservative phase of the study.
  • Proteinuria as measured by Uprot/Ucr > 4.0 on a spot sample aliquot from a 24-hour urine collection. The choice of Uprot/UCr is in accord with recent NKF-CKD guidelines.[9]
  • Estimated GFR ≥ 40 ml/min/1.73m2 while taking ACEI/ARB therapy. The GFR will be estimated using the 4 variable MDRD equation as published in the NKF-CKD guidelines.[9] The same NKF-CKD guidelines also promote the use of estimated GFR (GFRest) values rather than serum creatinine levels or CrCl measurements as the preferred non-invasive method of determining glomerular filtration rates.[9]

Exclusion Criteria:• Age <18 years.

  • Estimated GFR < 40 ml/min/1.73m2, or serum creatinine >2.0 mg/dl.
  • Renal biopsy showing more than 30% glomerulosclerosis and/or tubular atrophy.
  • Patient must be off glucocorticoid, calcineurin inhibitors (cyclosporin A, tacrolimus) or mycophenolic mofetil for > 1 month, and alkylating agents or rituximab for >6 months.
  • Resistance to the following immunosuppressive routines e.g. steroids alone, calcineurin inhibitors plus or minus steroids, cytotoxic agents plus or minus steroids.
  • Patients with active infections or secondary causes of MN (e.g. hepatitis B, SLE, medications, malignancies). Testing for HIV, Hepatitis B and C should have occurred < 2 years prior to enrollment into the study.
  • Type 1 or 2 diabetes mellitus: to exclude proteinuria secondary to diabetic nephropathy. Patients who have recent history of steroid induced diabetes but no evidence on renal biopsy performed within 6 months of entry into the study are eligible for enrollment.
  • Pregnancy or nursing - for safety reasons.
  • Acute renal vein thrombosis documented prior to entry by renal US or CT scan and requiring anticoagulation therapy.
Sexes Eligible for Study: All
18 Years to 72 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Health Canada ( Registry Identifier: Health Canada 4727-88\3-23 C., control 131403 )
Not Provided
Not Provided
University Health Network, Toronto
University Health Network, Toronto
Principal Investigator: Daniel Cattran, M.D University Health Network, Toronto
University Health Network, Toronto
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP